Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults

医学 随机对照试验 不利影响 2019年冠状病毒病(COVID-19) 中期分析 入射(几何) 临时的 内科学 严重急性呼吸综合征冠状病毒2型(SARS-CoV-2) 疾病 历史 光学 物理 考古 传染病(医学专业)
作者
Nawal Al Kaabi,Yuntao Zhang,Shengli Xia,Yunkai Yang,Manaf M. Al Qahtani,Najiba M. Abdulrazzaq,Majed Al Nusair,Mohamed Hassany,Jaleela S. Jawad,Jehad Abdalla,Salah Eldin Hussein,Shamma K. Al Mazrouei,Maysoon Al Karam,Xinguo Li,Xuqin Yang,Wei Wang,Bonan Lai,Wei Chen,Shihe Huang,Qian Wang
出处
期刊:JAMA [American Medical Association]
被引量:772
标识
DOI:10.1001/jama.2021.8565
摘要

Importance

Although effective vaccines against COVID-19 have been developed, additional vaccines are still needed.

Objective

To evaluate the efficacy and adverse events of 2 inactivated COVID-19 vaccines.

Design, Setting, and Participants

Prespecified interim analysis of an ongoing randomized, double-blind, phase 3 trial in the United Arab Emirates and Bahrain among adults 18 years and older without known history of COVID-19. Study enrollment began on July 16, 2020. Data sets used for the interim analysis of efficacy and adverse events were locked on December 20, 2020, and December 31, 2020, respectively.

Interventions

Participants were randomized to receive 1 of 2 inactivated vaccines developed from SARS-CoV-2 WIV04 (5 µg/dose; n = 13 459) and HB02 (4 µg/dose; n = 13 465) strains or an aluminum hydroxide (alum)–only control (n = 13 458); they received 2 intramuscular injections 21 days apart.

Main Outcomes and Measures

The primary outcome was efficacy against laboratory-confirmed symptomatic COVID-19 14 days following a second vaccine dose among participants who had no virologic evidence of SARS-CoV-2 infection at randomization. The secondary outcome was efficacy against severe COVID-19. Incidence of adverse events and reactions was collected among participants who received at least 1 dose.

Results

Among 40 382 participants randomized to receive at least 1 dose of the 2 vaccines or alum-only control (mean age, 36.1 years; 32 261 [84.4%] men), 38 206 (94.6%) who received 2 doses, contributed at least 1 follow-up measure after day 14 following the second dose, and had negative reverse transcriptase–polymerase chain reaction test results at enrollment were included in the primary efficacy analysis. During a median (range) follow-up duration of 77 (1-121) days, symptomatic COVID-19 was identified in 26 participants in the WIV04 group (12.1 [95% CI, 8.3-17.8] per 1000 person-years), 21 in the HB02 group (9.8 [95% CI, 6.4-15.0] per 1000 person-years), and 95 in the alum-only group (44.7 [95% CI, 36.6-54.6] per 1000 person-years), resulting in a vaccine efficacy, compared with alum-only, of 72.8% (95% CI, 58.1%-82.4%) for WIV04 and 78.1% (95% CI, 64.8%-86.3%) for HB02 (P < .001 for both). Two severe cases of COVID-19 occurred in the alum-only group and none occurred in the vaccine groups. Adverse reactions 7 days after each injection occurred in 41.7% to 46.5% of participants in the 3 groups; serious adverse events were rare and similar in the 3 groups (WIV04: 64 [0.5%]; HB02: 59 [0.4%]; alum-only: 78 [0.6%]).

Conclusions and Relevance

In this prespecified interim analysis of a randomized clinical trial, treatment of adults with either of 2 inactivated SARS-CoV-2 vaccines significantly reduced the risk of symptomatic COVID-19, and serious adverse events were rare. Data collection for final analysis is pending.

Trial Registration

ClinicalTrials.gov Identifier:NCT04510207; Chinese Clinical Trial Registry:ChiCTR2000034780
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
pluto应助Vera采纳,获得10
刚刚
lllllllll发布了新的文献求助10
刚刚
Chen发布了新的文献求助10
1秒前
星星完成签到,获得积分10
1秒前
1秒前
tyro发布了新的文献求助200
1秒前
Xwu完成签到,获得积分10
1秒前
Jingzi完成签到,获得积分10
1秒前
1秒前
BL发布了新的文献求助10
2秒前
迟早year完成签到 ,获得积分10
2秒前
九天揽月完成签到,获得积分10
3秒前
龚兴艳完成签到,获得积分20
3秒前
观鹤轩完成签到 ,获得积分10
3秒前
杨亦凡的吴完成签到,获得积分10
4秒前
5秒前
5秒前
aqaqaqa完成签到,获得积分10
5秒前
Tsui发布了新的文献求助10
5秒前
mumu发布了新的文献求助10
6秒前
7秒前
XJ发布了新的文献求助10
9秒前
活力青筠完成签到,获得积分10
9秒前
张凌霄完成签到,获得积分10
9秒前
shinn发布了新的文献求助10
10秒前
10秒前
量子星尘发布了新的文献求助10
10秒前
元g完成签到,获得积分20
10秒前
11秒前
喝酸奶不舔盖完成签到 ,获得积分10
11秒前
乐乐应助Chen采纳,获得10
11秒前
在水一方应助迷人芙蓉采纳,获得10
13秒前
ssstuck发布了新的文献求助10
14秒前
bingshuaizhao发布了新的文献求助10
14秒前
无问西东完成签到 ,获得积分10
15秒前
Owen应助科研通管家采纳,获得10
16秒前
Akim应助科研通管家采纳,获得10
16秒前
柯一一应助科研通管家采纳,获得10
16秒前
852应助科研通管家采纳,获得10
17秒前
酷波er应助科研通管家采纳,获得10
17秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975339
求助须知:如何正确求助?哪些是违规求助? 3519670
关于积分的说明 11199199
捐赠科研通 3256002
什么是DOI,文献DOI怎么找? 1798043
邀请新用户注册赠送积分活动 877386
科研通“疑难数据库(出版商)”最低求助积分说明 806305